402 related articles for article (PubMed ID: 24568585)
1. Human CDC2-like kinase 1 (CLK1): a novel target for Alzheimer's disease.
Jain P; Karthikeyan C; Moorthy NS; Waiker DK; Jain AK; Trivedi P
Curr Drug Targets; 2014 May; 15(5):539-50. PubMed ID: 24568585
[TBL] [Abstract][Full Text] [Related]
2. Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing.
Fedorov O; Huber K; Eisenreich A; Filippakopoulos P; King O; Bullock AN; Szklarczyk D; Jensen LJ; Fabbro D; Trappe J; Rauch U; Bracher F; Knapp S
Chem Biol; 2011 Jan; 18(1):67-76. PubMed ID: 21276940
[TBL] [Abstract][Full Text] [Related]
3. Structural Basis for the Selective Inhibition of Cdc2-Like Kinases by CX-4945.
Lee JY; Yun JS; Kim WK; Chun HS; Jin H; Cho S; Chang JH
Biomed Res Int; 2019; 2019():6125068. PubMed ID: 31531359
[TBL] [Abstract][Full Text] [Related]
4. Regulation of influenza A virus mRNA splicing by CLK1.
Artarini A; Meyer M; Shin YJ; Huber K; Hilz N; Bracher F; Eros D; Orfi L; Keri G; Goedert S; Neuenschwander M; von Kries J; Domovich-Eisenberg Y; Dekel N; Szabadkai I; Lebendiker M; Horváth Z; Danieli T; Livnah O; Moncorgé O; Frise R; Barclay W; Meyer TF; Karlas A
Antiviral Res; 2019 Aug; 168():187-196. PubMed ID: 31176694
[TBL] [Abstract][Full Text] [Related]
5. Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing.
Debdab M; Carreaux F; Renault S; Soundararajan M; Fedorov O; Filippakopoulos P; Lozach O; Babault L; Tahtouh T; Baratte B; Ogawa Y; Hagiwara M; Eisenreich A; Rauch U; Knapp S; Meijer L; Bazureau JP
J Med Chem; 2011 Jun; 54(12):4172-86. PubMed ID: 21615147
[TBL] [Abstract][Full Text] [Related]
6. Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview.
Lindberg MF; Meijer L
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34205123
[TBL] [Abstract][Full Text] [Related]
7. Structure-Activity Relationship in the Leucettine Family of Kinase Inhibitors.
Tahtouh T; Durieu E; Villiers B; Bruyère C; Nguyen TL; Fant X; Ahn KH; Khurana L; Deau E; Lindberg MF; Sévère E; Miege F; Roche D; Limanton E; L'Helgoual'ch JM; Burgy G; Guiheneuf S; Herault Y; Kendall DA; Carreaux F; Bazureau JP; Meijer L
J Med Chem; 2022 Jan; 65(2):1396-1417. PubMed ID: 34928152
[TBL] [Abstract][Full Text] [Related]
8. Discovery of DB18, a potent inhibitor of CLK kinases with a high selectivity against DYRK1A kinase.
Brahmaiah D; Kanaka Durga Bhavani A; Aparna P; Sampath Kumar N; Solhi H; Le Guevel R; Baratte B; Ruchaud S; Bach S; Singh Jadav S; Raji Reddy C; Roisnel T; Mosset P; Levoin N; Grée R
Bioorg Med Chem; 2021 Feb; 31():115962. PubMed ID: 33422908
[TBL] [Abstract][Full Text] [Related]
9. Marine-Derived 2-Aminoimidazolone Alkaloids. Leucettamine B-Related Polyandrocarpamines Inhibit Mammalian and Protozoan DYRK & CLK Kinases.
Loaëc N; Attanasio E; Villiers B; Durieu E; Tahtouh T; Cam M; Davis RA; Alencar A; Roué M; Bourguet-Kondracki ML; Proksch P; Limanton E; Guiheneuf S; Carreaux F; Bazureau JP; Klautau M; Meijer L
Mar Drugs; 2017 Oct; 15(10):. PubMed ID: 29039762
[TBL] [Abstract][Full Text] [Related]
10. Kororamides, Convolutamines, and Indole Derivatives as Possible Tau and Dual-Specificity Kinase Inhibitors for Alzheimer's Disease: A Computational Study.
Llorach-Pares L; Nonell-Canals A; Avila C; Sanchez-Martinez M
Mar Drugs; 2018 Oct; 16(10):. PubMed ID: 30332805
[TBL] [Abstract][Full Text] [Related]
11. Novel CLK1 inhibitors based on N-aryloxazol-2-amine skeleton - A possible way to dual VEGFR2 TK/CLK ligands.
Murár M; Dobiaš J; Šramel P; Addová G; Hanquet G; Boháč A
Eur J Med Chem; 2017 Jan; 126():754-761. PubMed ID: 27940419
[TBL] [Abstract][Full Text] [Related]
12. New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis.
Tazarki H; Zeinyeh W; Esvan YJ; Knapp S; Chatterjee D; Schröder M; Joerger AC; Khiari J; Josselin B; Baratte B; Bach S; Ruchaud S; Anizon F; Giraud F; Moreau P
Eur J Med Chem; 2019 Mar; 166():304-317. PubMed ID: 30731399
[TBL] [Abstract][Full Text] [Related]
13. Molecular structures of cdc2-like kinases in complex with a new inhibitor chemotype.
Walter A; Chaikuad A; Helmer R; Loaëc N; Preu L; Ott I; Knapp S; Meijer L; Kunick C
PLoS One; 2018; 13(5):e0196761. PubMed ID: 29723265
[TBL] [Abstract][Full Text] [Related]
14. Mobilization of a splicing factor through a nuclear kinase-kinase complex.
Aubol BE; Keshwani MM; Fattet L; Adams JA
Biochem J; 2018 Feb; 475(3):677-690. PubMed ID: 29335301
[TBL] [Abstract][Full Text] [Related]
15. Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B.
Tahtouh T; Elkins JM; Filippakopoulos P; Soundararajan M; Burgy G; Durieu E; Cochet C; Schmid RS; Lo DC; Delhommel F; Oberholzer AE; Pearl LH; Carreaux F; Bazureau JP; Knapp S; Meijer L
J Med Chem; 2012 Nov; 55(21):9312-30. PubMed ID: 22998443
[TBL] [Abstract][Full Text] [Related]
16. Clk/STY (cdc2-like kinase 1) and Akt regulate alternative splicing and adipogenesis in 3T3-L1 pre-adipocytes.
Li P; Carter G; Romero J; Gower KM; Watson J; Patel NA; Cooper DR
PLoS One; 2013; 8(1):e53268. PubMed ID: 23308182
[TBL] [Abstract][Full Text] [Related]
17. Leucettine L41, a DYRK1A-preferential DYRKs/CLKs inhibitor, prevents memory impairments and neurotoxicity induced by oligomeric Aβ25-35 peptide administration in mice.
Naert G; Ferré V; Meunier J; Keller E; Malmström S; Givalois L; Carreaux F; Bazureau JP; Maurice T
Eur Neuropsychopharmacol; 2015 Nov; 25(11):2170-82. PubMed ID: 26381812
[TBL] [Abstract][Full Text] [Related]
18. Systematic diversification of benzylidene heterocycles yields novel inhibitor scaffolds selective for Dyrk1A, Clk1 and CK2.
Mariano M; Hartmann RW; Engel M
Eur J Med Chem; 2016 Apr; 112():209-216. PubMed ID: 26896709
[TBL] [Abstract][Full Text] [Related]
19. A conserved sequence motif bridges two protein kinases for enhanced phosphorylation and nuclear function of a splicing factor.
Aubol BE; Fattet L; Adams JA
FEBS J; 2021 Jan; 288(2):566-581. PubMed ID: 32359191
[TBL] [Abstract][Full Text] [Related]
20. N-terminus of the protein kinase CLK1 induces SR protein hyperphosphorylation.
Aubol BE; Plocinik RM; Keshwani MM; McGlone ML; Hagopian JC; Ghosh G; Fu XD; Adams JA
Biochem J; 2014 Aug; 462(1):143-52. PubMed ID: 24869919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
